

Jerzy Jankun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8308198/publications.pdf>

Version: 2024-02-01

82

papers

2,441

citations

279798

23

h-index

223800

46

g-index

83

all docs

83

docs citations

83

times ranked

3141

citing authors

#	ARTICLE	IF	CITATIONS
1	Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review). International Journal of Molecular Medicine, 2019, 43, 15-25.	4.0	20
2	A thousand words about the challenges of photodynamic therapy. Journal of Medical Science, 2019, 88, 195-199.	0.7	4
3	Can components of the plasminogen activation system predict the outcome of kidney transplants?. Central-European Journal of Immunology, 2018, 43, 222-230.	1.2	0
4	Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?. International Journal of Molecular Sciences, 2018, 19, 248.	4.1	17
5	Formulation and characterization of EGCG for the treatment of superficial bladder cancer. International Journal of Molecular Medicine, 2017, 40, 329-336.	4.0	19
6	Effects of chlorhexidine, essential oils and herbal medicines (Salvia, Chamomile, Calendula) on human fibroblast in vitro. Central-European Journal of Immunology, 2016, 2, 125-131.	1.2	11
7	Determining whether curcumin degradation/condensation is actually bioactivation (Review). International Journal of Molecular Medicine, 2016, 37, 1151-1158.	4.0	92
8	Clinical implications of the growth-suppressive effects of chlorhexidine at low and high concentrations on human gingival fibroblasts and changes in morphology. International Journal of Molecular Medicine, 2016, 37, 1594-1600.	4.0	40
9	Enamel matrix proteins exhibit growth factor activity: A review of evidence at the cellular and molecular levels. Experimental and Therapeutic Medicine, 2015, 9, 2025-2033.	1.8	14
10	Application of Long-Acting VLHL PAI-1 during Sutureless Partial Nephrectomy in Mice Reduces Bleeding. BioMed Research International, 2015, 2015, 1-7.	1.9	1
11	Experimental immunology Synergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cells. Central-European Journal of Immunology, 2015, 1, 1-4.	1.2	12
12	Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid. Experimental and Therapeutic Medicine, 2015, 9, 2339-2343.	1.8	11
13	Plasminogen activation system in oral cancer: Relevance in prognosis and therapy (Review). International Journal of Oncology, 2015, 47, 16-24.	3.3	10
14	Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model. International Journal of Oncology, 2014, 44, 147-152.	3.3	17
15	Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives. Oncology Letters, 2014, 7, 17-22.	1.8	20
16	Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer. BioMed Research International, 2014, 2014, 1-7.	1.9	9
17	Unusual clotting dynamics of plasma supplemented with iron(III). International Journal of Molecular Medicine, 2014, 33, 367-372.	4.0	22
18	The plasminogen activation system in periodontal tissue (Review). International Journal of Molecular Medicine, 2014, 33, 763-768.	4.0	21

#	ARTICLE	IF	CITATIONS
19	Plasminogen activator inhibitor-1 in kidney pathology. International Journal of Molecular Medicine, 2013, 31, 503-510.	4.0	65
20	Analysis of the inhibition of PAI-1 by metal theaflavin complexes and their degradation products. International Journal of Molecular Medicine, 2013, 31, 1153-1158.	4.0	5
21	Isolation and characterization of serum albumin from Camelus dromedarius. Experimental and Therapeutic Medicine, 2013, 6, 519-524.	1.8	6
22	The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate. Wspolczesna Onkologia, 2013, 4, 389-393.	1.4	2
23	Experimental immunology Complex function of magnesium in blood clot formation and lysis. Central-European Journal of Immunology, 2013, 2, 149-153.	1.2	13
24	Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients. Cardiovascular & Hematological Disorders Drug Targets, 2013, 13, 144-150.	0.7	6
25	If Nature Failed Creating the Perfect Prostate Could Inhibitors of Proteolysis Help?. , 2013, 02, .		0
26	A study of the anti-diabetic agents of camel milk. International Journal of Molecular Medicine, 2012, 30, 585-592.	4.0	82
27	Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer. Oncology Reports, 2012, 28, 1275-1282.	2.6	19
28	Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report. Experimental and Therapeutic Medicine, 2012, 4, 661-664.	1.8	6
29	Probing Dimerization and Structural Flexibility of Mammalian Lipoxygenases by Small-Angle X-ray Scattering. Journal of Molecular Biology, 2011, 409, 654-668.	4.2	37
30	Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea. International Journal of Molecular Medicine, 2011, 27, 525-9.	4.0	16
31	Protein-based nanotechnology: Antibody conjugated with photosensitizer in targeted anticancer photoimmunotherapy. International Journal of Oncology, 2011, 39, 949-53.	3.3	6
32	Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review). International Journal of Molecular Medicine, 2011, 29, 3-11.	4.0	23
33	Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. International Journal of Molecular Medicine, 2011, 29, 61-4.	4.0	16
34	Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model. BJU International, 2010, 105, 1469-1476.	2.5	16
35	Platelet 12-lipoxygenase and stem cells in Barrett's esophagus. Oncology Letters, 2010, 1, 789-791.	1.8	1
36	Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss. International Journal of Molecular Medicine, 2010, 26, 501-4.	4.0	12

#	ARTICLE	IF	CITATIONS
37	Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 575-577.	1.8	12
38	Theaflavin digallate inactivates plasminogen activator inhibitor: Could tea help in Alzheimer's disease and obesity?. <i>International Journal of Molecular Medicine</i> , 2010, 26, 45-50.	4.0	21
39	Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. <i>Pharmacological Reports</i> , 2009, 61, 673-680.	3.3	13
40	Human platelet 12-lipoxygenase: Naturally occurring Q261/R261 variants and N544L mutant show altered activity but unaffected substrate binding and membrane association behavior. <i>International Journal of Molecular Medicine</i> , 2009, 24, 759-64.	4.0	17
41	VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form. <i>International Journal of Molecular Medicine</i> , 2009, 23, 57-63.	4.0	1
42	Yin and yang of the plasminogen activator inhibitor. , 2009, 119, 410-7.		11
43	Human Platelet 12-Lipoxygenase, New Findings about Its Activity, Membrane Binding and Low-resolution Structure. <i>Journal of Molecular Biology</i> , 2008, 376, 193-209.	4.2	63
44	Do Human Lipoxygenases have a PDZ Regulatory Domain?. <i>Current Molecular Medicine</i> , 2008, 8, 768-773.	1.3	9
45	An Energy-Based Segmentation of Prostate from Ultrasound Images using Dot-Pattern Select Cells. , 2007, , .		11
46	PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. <i>International Journal of Molecular Medicine</i> , 2007, 20, 11.	4.0	4
47	Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development. <i>Current Enzyme Inhibition</i> , 2007, 3, 119-132.	0.4	26
48	PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. <i>International Journal of Molecular Medicine</i> , 2007, 20, 11-20.	4.0	10
49	Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. <i>International Journal of Molecular Medicine</i> , 2007, 20, 683-7.	4.0	16
50	Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1371-1382.	4.1	51
51	Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity. <i>International Journal of Molecular Medicine</i> , 2006, 17, 437.	4.0	4
52	Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase. <i>Prostate</i> , 2006, 66, 779-787.	2.3	31
53	Nutraceutical inhibitors of urokinase: Potential applications in prostate cancer prevention and treatment. <i>Oncology Reports</i> , 2006, 16, 341.	2.6	6
54	Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity. <i>International Journal of Molecular Medicine</i> , 2006, 17, 437-47.	4.0	5

#	ARTICLE	IF	CITATIONS
55	Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment. <i>Oncology Reports</i> , 2006, 16, 341-6.	2.6	17
56	Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. <i>BJU International</i> , 2005, 95, 1237-1244.	2.5	53
57	Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2-mediated PDT. <i>Physics in Medicine and Biology</i> , 2004, 49, 3209-3225.	3.0	22
58	Plasminogen activator inhibitor type-1: Its structure, biological activity and role in tumorigenesis (Review). <i>International Journal of Molecular Medicine</i> , 2004, 13, 759.	4.0	11
59	Soybean lipoxygenase-3 in complex with 4-nitrocatechol. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 613-615.	2.5	25
60	OPTICAL CHARACTERISTICS OF THE CANINE PROSTATE AT 665 NM SENSITIZED WITH TIN ETIOPURPURIN DICHLORIDE: NEED FOR REAL-TIME MONITORING OF PHOTODYNAMIC THERAPY. <i>Journal of Urology</i> , 2004, 172, 739-743.	0.4	35
61	Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). <i>International Journal of Molecular Medicine</i> , 2004, 13, 759-66.	4.0	21
62	Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. <i>Oncology Reports</i> , 2004, 12, 1155-62.	2.6	7
63	Lipoxygenase interactions with natural flavonoid, quercetin, reveal a complex with protocatechuic acid in its X-ray structure at 2.1 Å... resolution. <i>Proteins: Structure, Function and Bioinformatics</i> , 2003, 54, 13-19.	2.6	72
64	Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 Å... reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead. <i>International Journal of Molecular Medicine</i> , 2003, 12, 415.	4.0	27
65	Structure of curcumin in complex with lipoxygenase and its significance in cancer. <i>International Journal of Molecular Medicine</i> , 2003, 12, 17.	4.0	20
66	Control of the Aggressive Capacity of Prostate Cancer by Nutritional Inhibitors of Urokinase and Lipoxygenase. <i>International Journal of Human Genetics</i> , 2003, 3, 127-134.	0.1	0
67	A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 19-28.	4.1	13
68	Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy. <i>International Journal of Molecular Medicine</i> , 2003, 11, 287-91.	4.0	8
69	Structure of curcumin in complex with lipoxygenase and its significance in cancer. <i>International Journal of Molecular Medicine</i> , 2003, 12, 17-24.	4.0	52
70	Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 Å reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead. <i>International Journal of Molecular Medicine</i> , 2003, 12, 415-20.	4.0	54
71	Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. <i>Oncology Reports</i> , 2001, 8, 463-70.	2.6	43
72	Computer model for photodynamic therapy of the prostate. , 2000, 3907, 222.		9

#	ARTICLE	IF	CITATIONS
73	Curcumin inhibits lipoyxygenase by binding to its central cavity: theoretical and X-ray evidence.. International Journal of Molecular Medicine, 2000, 6, 521-6.	4.0	104
74	Computer Model for Cryosurgery of the Prostate. Computer Aided Surgery, 1999, 4, 193-199.	1.8	22
75	Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.. Oncology Reports, 1999, 6, 523-6.	2.6	37
76	Structural and Thermochemical Characterization of Lipoyxygenase~Catechol Complexes. Biochemistry, 1998, 37, 17952-17957.	2.5	29
77	Why drinking green tea could prevent cancer. Nature, 1997, 387, 561-561.	27.8	656
78	Targeting of Drugs to Tumors: The Use of the Plasminogen Activator Inhibitor as a Ligand. , 1994, , 67-79.		1
79	Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. Journal of Cellular Biochemistry, 1993, 53, 135-144.	2.6	87
80	Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. International Journal of Molecular Medicine, 0, , .	4.0	11
81	COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs.. Translation the University of Toledo Journal of Medical Sciences, 0, 7, 1-5.	0.0	16
82	Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncology Reports, 0, , .	2.6	7